osocimab   Click here for help

GtoPdb Ligand ID: 11366

Synonyms: BAY 1213790 | BAY-1213790 | BAY1213790
Compound class: Antibody
Comment: Osocimab (BAY 1213790) is a fully humanized monoclonal antibody that targets activated Factor XI [1]. It is being investigated for clinical prevention of thrombosis [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Osocimab has been advanced to clinical trial for prevention of thrombosis in select patient groups [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03276143 FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty Phase 2 Interventional Bayer Compared with enoxaparin, osocimab met criteria for superiority in preventing post-operative venous thromboembolism. 2
NCT04523220 Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis Phase 2 Interventional Bayer